Schreder Karsten, Wickenhauser Claudia, Kappler Matthias, Tavassol Frank, Eckert Alexander W
Martin Luther University Halle-Wittenberg, University Hospital, Department of Oral and Maxillofacial Plastic Surgery, Halle (Saale), Germany.
Dental Office, Maxillofacial Surgery, Alexander Raue, Dres. Schäfer, Halle (Saale), Germany.
GMS Interdiscip Plast Reconstr Surg DGPW. 2025 Apr 16;14:Doc01. doi: 10.3205/iprs000190. eCollection 2025.
Oral squamous cell carcinoma (OSCC) is one of the most common malignant tumors worldwide with an increasing incidence. The surgical treatment is challenging and often requires the entire repertoire of plastic surgery. Diagnostically only a few crucial parameters are in use and even less for an individual and specific drug targeting. An individualised prognostic calculation is unavoidable to be able to adapt very complex surgical processes to an acceptable level. Unfortunately, the classic TNM system and grading are no longer sufficient, especially for individualized prognosis. Moreover, despite advances in treatment, studies have shown that the prognosis of patients with OSCC in terms of survival rate has not improved significantly, which is mainly due to the presence of treatment-resistant OSCC. Therefore, the identification of new, reliable biomarkers for early diagnosis and drug targets of OSCC is urgently needed. Meanwhile, the abundance of potential biomarkers for OSCC is difficult to keep track of. Therefore, the aim of the article was to provide an overview of articles listed in Pubmed that deal with the topic of biomarkers in oral squamous cell carcinoma, focusing in particular on the topic metabolism. Another question of this study was to set the focus on essential additive metabolic biomarkers, which can also be easily used in clinical routine.
口腔鳞状细胞癌（OSCC）是全球最常见的恶性肿瘤之一，发病率呈上升趋势。手术治疗具有挑战性，通常需要整形手术的全部技能。在诊断方面，目前仅使用少数关键参数，而针对个体和特定药物靶点的参数更少。为了使非常复杂的手术过程达到可接受的水平，个性化的预后计算是不可避免的。不幸的是，经典的TNM系统和分级已不再足够，特别是对于个性化预后而言。此外，尽管治疗取得了进展，但研究表明，OSCC患者的生存率预后并未显著改善，这主要是由于存在对治疗耐药的OSCC。因此，迫切需要鉴定用于OSCC早期诊断和药物靶点的新的、可靠的生物标志物。同时，OSCC潜在生物标志物的数量众多，难以追踪。因此，本文的目的是概述发表在PubMed上的涉及口腔鳞状细胞癌生物标志物主题的文章，特别关注代谢主题。本研究的另一个问题是将重点放在重要的附加代谢生物标志物上，这些标志物也可轻松应用于临床常规。
